Abstract

In RATIONALE-303 (NCT03358875) tislelizumab significantly improved OS vs docetaxel in the ITT population at the interim analysis (IA), based upon which, tislelizumab was approved in China for treatment of advanced NSCLC patients with progressive disease after chemotherapy. Here, we report outcomes of the final analysis (FA) and post hoc biomarker analysis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call